Atea Pharmaceuticals, Inc.

AVIR
$4.88 (- $0.10 - 2.01%)
Last updated: 2026-07-06 20:54 UTC
AVIR Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS04683R1068
CUSIP04683R106
Market Price4.88
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.77
Market Cap$268.0M
Book Value4.04
Price to Book0.849
Beta0.16
52w High4.02
52w Low2.46
Next Earnings DateN/A

Atea Pharmaceuticals, Inc. trades under ticker AVIR on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US04683R1068, CUSIP 04683R106.

About the Company
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Price History